CGEN
Price
$2.31
Change
-$0.02 (-0.85%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
227.37M
45 days until earnings call
Intraday BUY SELL Signals
RCUS
Price
$24.46
Change
-$0.77 (-3.05%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.18B
39 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGEN vs RCUS

CGEN vs RCUS Comparison Chart in %
View a ticker or compare two or three
VS
CGEN vs. RCUS commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and RCUS is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CGEN vs RCUS: Fundamental Ratings
CGEN
RCUS
OUTLOOK RATING
1..100
1477
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2098
PRICE GROWTH RATING
1..100
4445
P/E GROWTH RATING
1..100
3298
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CGEN's Valuation (56) in the Biotechnology industry is in the same range as RCUS (71) in the Pharmaceuticals Major industry. This means that CGEN’s stock grew similarly to RCUS’s over the last 12 months.

CGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that CGEN’s stock grew similarly to RCUS’s over the last 12 months.

CGEN's SMR Rating (20) in the Biotechnology industry is significantly better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that CGEN’s stock grew significantly faster than RCUS’s over the last 12 months.

CGEN's Price Growth Rating (44) in the Biotechnology industry is in the same range as RCUS (45) in the Pharmaceuticals Major industry. This means that CGEN’s stock grew similarly to RCUS’s over the last 12 months.

CGEN's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that CGEN’s stock grew significantly faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENRCUS
RSI
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 23 days ago
87%
Bearish Trend 8 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (CGEN: $2.34 vs. RCUS: $25.23)
Brand notoriety: CGEN and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 52% vs. RCUS: 92%
Market capitalization -- CGEN: $227.37M vs. RCUS: $3.18B
CGEN [@Biotechnology] is valued at $227.37M. RCUS’s [@Biotechnology] market capitalization is $3.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 2 FA rating(s) are green while RCUS’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 2 green, 3 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, CGEN is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 3 bullish, 7 bearish.
  • RCUS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than CGEN.

Price Growth

CGEN (@Biotechnology) experienced а -1.27% price change this week, while RCUS (@Biotechnology) price change was +0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

CGEN is expected to report earnings on Nov 16, 2026.

RCUS is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CGEN
Daily Signal:
Gain/Loss:
RCUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPDG44.960.32
+0.72%
State Street SPDR Portfolio S&P Sector Neutral Dividend ETF (SPDG)
BSTP40.17N/A
-0.01%
Innovator Buffer Step-Up Strategy ETF (BSTP)
OUSA59.45-0.03
-0.05%
ALPS O'Shares U.S. Quality Dividend ETF (OUSA)
SCHI21.38-0.06
-0.28%
Schwab 5-10 Year Corporate Bond ETF (SCHI)
BEEX27.12-0.09
-0.33%
Beehive ETF (BEEX)

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-2.32%
VIR - RCUS
49%
Loosely correlated
+0.98%
XNCR - RCUS
49%
Loosely correlated
-0.72%
KURA - RCUS
46%
Loosely correlated
-0.56%
NRIX - RCUS
44%
Loosely correlated
-1.56%
BCAX - RCUS
44%
Loosely correlated
-2.20%
More